Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Eligibility Criteria

• 1. Provision of signed and dated informed consent form
• 2. Female, aged 18-50 years old
• 3. Diagnosis of sickle cell disease (SS, SB0,SB+,SC)
• 4. Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
• 5. At least 1 and no more than 10 medical presentations (e.g. hospitalization, emergency room visit, outpatient infusion visit) for sickle cell-related pain during the past year
• 6. Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month since last use of all hormonal contraception, and 4 months since most recent administration of depot medroxyprogesterone, is required prior to enrollment in the study.
• 7. Stable dose of hydroxyurea and other sickle cell-related medications for the past 6 months
• 8. Access to a device with text-messaging capability
• 9. Must be able to read and understand English
• 10. Willing to comply with study procedures
• 1. Chronic inflammatory conditions, such as lupus or inflammatory bowel disease
• 2. History of VTE or stroke
• 3. Current use of crizanlizumab, voxelotor, or red cell exchange transfusion, or history of hematopoietic stem cell transplantation
• 4. Current use of hormonal contraception or the copper intrauterine device
• 5. Current pregnancy or pregnancy within the last 6 months
• 6. Current lactation
• 7. Polycystic ovary syndrome or irregular periods
• 8. Blood pressure \>= 160 systolic or \>=100 diastolic at screening visit